Dextera Biosciences

Dextera Biosciences is developing a groundbreaking therapeutic platform based on synthetic D-amino acid proteins (dexabodies). This technology offers significant potential advantages over conventional biologics, including superior stability, tissue penetration, and the ability to precisely deliver therapeutic payloads. Led by an experienced team with a track record in company creation and drug development, Dextera is targeting high-need disease areas where current treatments are inadequate. The company is in a pre-clinical, pre-revenue stage, building its platform and pipeline.

Synthetic D-Protein platform producing 'dexabodies'—therapeutics built from D-amino acids that are protease-resistant, small (1/20th antibody size), and enable deep tissue penetration and precise payload delivery.

Dextera competes in the crowded next-generation biologic space against companies developing improved ADCs, bispecific antibodies, and peptide therapies. Its unique differentiator is the all-D-amino acid backbone, which, if successful, could provide a significant stability and penetration advantage over these modalities.